If you have a question for our guest, host or DRG please submit it here.
The advantages of onsite manufacturing facilities for clinical trials
Guest: Bill Newell, CEO, Sutro Biopharma
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Bill Newell, CEO of Sutro Biopharma. Bill shared his views on the fundamental importance of ensuring patients, especially cancer patients, receive their treatment (as scheduled) despite pandemic related delays. He explained how they were uniquely positioned to continue trials and initial new ones safely and with minimal interruption due in large part to their onsite manufacturing facilities. Mike and Bill talked about how Sutro Biopharma successfully raised $98 million in a public offering through zoom calls which pre-pandemic would have been unheard of! They also explored the interesting dynamic they recently found themselves in when one of their major partners was acquired by another. Watch the full video for more.
About our Guest
Bill Newell, CEO, Sutro Biopharma
William J. Newell has served as Sutro's Chief Executive Officer and a member of the Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. William has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of a private biotechnology company, the Biotechnology Innovation Organization’s Health Section and Emerging Company Section and the California Life Sciences Association, where he also serves as a member of the executive committee. William received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.